Abstract
Alzheimers disease (AD) is characterized by the presence, in the brain of the patients, of two aberrant structures: intracellular neurofibrillary tangles (NFTs), containing an abnormal hyperphosphorylated form of tau protein, and extracellular senile plaques (SPs), mainly composed by fibrillar amyloid β peptide. Another feature of AD is the neurodegeneration and dysfunction of basal forebrain cholinergic system. A possible connection among those AD characteristics could occur. Thus, the purpose of this short review is to summarize the involvement of nicotinic (nAChR) and muscarinic (mAChR) receptors on tau phosphorylation, in a direct way, or through the previous interaction of some of these receptors with amyloid β. Several studies have demonstrated that nAChR activation results in a significantly increase of tau phosphorylation, whereas mAChR activation, may prevent tau phosphorylation.
Keywords: Alzheimer's disease, tau phosphorylation, amyloid b peptide, nicotinic receptors, muscarinic receptors, acetylcholine
Current Molecular Medicine
Title: Acetylcholine Receptors and Tau Phosphorylation
Volume: 6 Issue: 4
Author(s): A. Rubio, M. Pérez and Jesus Ávila
Affiliation:
Keywords: Alzheimer's disease, tau phosphorylation, amyloid b peptide, nicotinic receptors, muscarinic receptors, acetylcholine
Abstract: Alzheimers disease (AD) is characterized by the presence, in the brain of the patients, of two aberrant structures: intracellular neurofibrillary tangles (NFTs), containing an abnormal hyperphosphorylated form of tau protein, and extracellular senile plaques (SPs), mainly composed by fibrillar amyloid β peptide. Another feature of AD is the neurodegeneration and dysfunction of basal forebrain cholinergic system. A possible connection among those AD characteristics could occur. Thus, the purpose of this short review is to summarize the involvement of nicotinic (nAChR) and muscarinic (mAChR) receptors on tau phosphorylation, in a direct way, or through the previous interaction of some of these receptors with amyloid β. Several studies have demonstrated that nAChR activation results in a significantly increase of tau phosphorylation, whereas mAChR activation, may prevent tau phosphorylation.
Export Options
About this article
Cite this article as:
Rubio A., Pérez M. and Ávila Jesus, Acetylcholine Receptors and Tau Phosphorylation, Current Molecular Medicine 2006; 6 (4) . https://dx.doi.org/10.2174/156652406777435444
DOI https://dx.doi.org/10.2174/156652406777435444 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Amplicons as Vaccine Vectors
Current Gene Therapy Deleted in Colorectal Cancer (DCC) Pathfinding: Axon Guidance Gene Finally Turned Tumor Suppressor
Current Drug Targets Caspase-Independent Pathways of Programmed Cell Death: The Unraveling of New Targets of Cancer Therapy?
Current Cancer Drug Targets Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
Current Pharmaceutical Biotechnology Serum Testosterone and Cognitive Function in Ageing Male: Updating the Evidence
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Aurora Kinase Inhibitors in Head and Neck Cancer
Current Topics in Medicinal Chemistry Electromagnetic Energy as a Bridge Between Atomic and Cellular Levels in the Genetics Approach to Cancer Treatment
Current Topics in Medicinal Chemistry Bioactive Polyphenols from Healthy Diets and Forest Biomass
Current Nutrition & Food Science Editorial [Hot Topic:Drug Targets in Ageing and Age-Associated Diseases (Executive Editors: C. Caruso and E. Jirillo)]
Current Pharmaceutical Design Hypoxia Selects for a Quiescent, CML Stem/Leukemia Initiating- Like Population Dependent on CBP/Catenin Transcription
Current Molecular Pharmacology Targeting Cardiac Mast Cells: Pharmacological Modulation of the Local Renin-Angiotensin System
Current Pharmaceutical Design Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Advances in Research of Schiff-Base Metal Complexes as Potent Antioxidants
Current Medicinal Chemistry The Tachykinergic System as Avenues for Drug Intervention
Recent Patents on CNS Drug Discovery (Discontinued) Protocatechuic Acid and Human Disease Prevention: Biological Activities and Molecular Mechanisms
Current Medicinal Chemistry Lipid Nanoparticles to Deliver miRNA in Cancer
Current Pharmaceutical Biotechnology ERK Signaling Pathway Regulates Embryonic Survival and Eye Development in Goldfish, Carassius auratus
Current Molecular Medicine Antimicrobial Photodynamic Therapy to Kill Gram-negative Bacteria
Recent Patents on Anti-Infective Drug Discovery Graphical Abstracts
Current Nanoscience